Search

Your search keyword '"Cesana, Clara"' showing total 48 results
Start Over Author "Cesana, Clara"
48 results on '"Cesana, Clara"'

5. Concomitant JAK2 V617F mutation and rare e1a2 BCR-ABL1 transcript isoform in a patient with myeloproliferative neoplasm

Author

Soriani, Silvia, primary, Lauricella, Calogero, additional, Frungillo, Niccolò, additional, De Troia, Beatrice Boido, additional, Motta, Valentina, additional, Cesana, Clara, additional, Guido, Valentina, additional, De Canal, Gabriella, additional, De Paoli, Elena, additional, Veronese, Silvio, additional, Bonoldi, Emanuela, additional, and Romitti, Lorenza, additional

Published
2022
Full Text
View/download PDF

12. BCR/ABL1 Fluorescence In Situ Hybridization Fusion Signals on Both Copies of Chromosome 22 in a Philadelphia-Masked Chronic Myeloid Leukemia Case: Implication for the Therapy

Author

Soriani, Silvia, primary, Guido, Valentina, additional, Bertani, Giambattista, additional, Cesana, Clara, additional, Motta, Valentina, additional, De Canal, Gabriella, additional, De Paoli, Elena, additional, Veronese, Silvio, additional, Bonoldi, Emanuela, additional, and Romitti, Lorenza, additional

Published
2021
Full Text
View/download PDF

18. A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry

Author

Pennisi, Martina, Cesana, Clara, Cittone, Micol Giulia, Bandiera, Laura, Scarpati, Barbara, Mancini, Valentina, Soriani, Silvia, Veronese, Silvio, Truini, Mauro, Rossini, Silvano, and Cairoli, Roberto

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with aggressive clinical course and poor prognosis. Diagnosis is based on detection of CD4+ CD56+, CD123high, TCL-1+, and blood dendritic cell antigen-2/CD303+ blasts, together with the absence of lineage specific antigens on tumour cells. In this report we present a case of BPDCN presenting with extramedullary and bone marrow involvement, extensively studied by flow cytometry and immunohistochemistry, who achieved complete remission after acute lymphoblastic leukemia like chemotherapy and allogeneic hematopoietic stem cell transplantation.

Published
2017
Full Text
View/download PDF

19. Flow cytometry analysis of lymphocyte subsets in bronchoalveolar lavage: comparison between lung non-Hodgkin lymphomas and reactive diseases

Author

Cesana, Clara, primary, Scarpati, Barbara, additional, Brando, Bruno, additional, Scampini, Linda, additional, Liga, Giuseppa, additional, Klersy, Catherine, additional, Chiericozzi, Michele, additional, Zilioli, Vittorio Ruggero, additional, Rusconi, Chiara, additional, Nichelatti, Michele, additional, Fieschi, Stefano, additional, Torre, Massimo, additional, Vanzulli, Angelo, additional, Cairoli, Roberto, additional, and Rossini, Silvano, additional

Published
2016
Full Text
View/download PDF

20. Response of steroid‐refractory chronic graft‐versus‐host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles

Author

Bertani, Giambattista, primary, Santoleri, Luca, additional, Ferri, Ursula, additional, Marenco, Paola, additional, Grillo, Giovanni, additional, Zucchetti, Elisa, additional, Forno, Barbara, additional, Lando, Giuliana, additional, Scarpati, Barbara, additional, Cairoli, Roberto, additional, Rossini, Silvano, additional, and Cesana, Clara, additional

Published
2015
Full Text
View/download PDF

25. Rapid detection of t(15;17)(q24;q21) in acute promyelocytic leukaemia by microwave-assisted fluorescence in situ hybridization.

Author

Soriani, Silvia, Mura, Cinzia, Panico, Anna Rita, Scarpa, Anna Maria, Recchimuzzo, Patrizia, Dadati, Raffaella, Farioli, Renata, De Canal, Gabriella, Mura, Maria Angela, and Cesana, Clara

Abstract

Acute promyelocytic leukaemia (APL) is a hematologic malignancy characterized by the rearrangement of the PML and RARα genes, mostly due to a reciprocal chromosomal translocation t(15;17)(q24;q21). A quick APL diagnosis is essential for starting a prompt suitable therapy. We describe a new rapid diagnostic laboratory approach to detect the PML-RARα rearrangement, which gives clear genetic results within 30 min of hybridization. It combines quick cell harvesting, fluorescence in situ hybridization performed with commercial DNA probe and microwave beams supplied by a domestic microwave oven. Copyright © 2015 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

28. Regeneration-associated WNT Signaling Is Activated in Long-term Reconstituting AC133bright Acute Myeloid Leukemia Cells

Author

Beghini, Alessandro, primary, Corlazzoli, Francesca, additional, Del Giacco, Luca, additional, Re, Matteo, additional, Lazzaroni, Francesca, additional, Brioschi, Matteo, additional, Valentini, Giorgio, additional, Ferrazzi, Fulvia, additional, Ghilardi, Anna, additional, Righi, Marco, additional, Turrini, Mauro, additional, Mignardi, Marco, additional, Cesana, Clara, additional, Bronte, Vincenzo, additional, Nilsson, Mats, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2012
Full Text
View/download PDF

30. Long-Term Surveillance of Allogeneic and Autologous Hemopoietic Stem Cell Transplant Recipients Affected by Primary Occult Hepatitis B Virus Infection

Author

Cairoli, Roberto, primary, Mancini, Luigi, additional, Bertani, Giambattista, additional, Angelis, Maria Luisa De, additional, Vantaggiato, Nadia, additional, Cesana, Clara, additional, Mancini, Valentina, additional, Morra, Enrica, additional, Ribero, Maria Lisa, additional, and Tagger, Alessandro, additional

Published
2010
Full Text
View/download PDF

31. Clinical Follow-up Demonstrates Differential Accuracy of Flow Cytometry and Cytomorphology for the Detection of Hematologic Malignancy in Hypercellular Body Cavity Fluids.

Author

Cesana, Clara, primary, Klersy, Catherine, additional, Scarpati, Barbara, additional, Brando, Bruno, additional, Volpato, Elisabetta, additional, Bertani, Giambattista, additional, Faleri, Maurizio, additional, Nosari, Annamaria, additional, Cantoni, Silvia, additional, Ferri, Ursula, additional, Scampini, Linda, additional, Barba, Claudia, additional, Lando, Giuliana, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2009
Full Text
View/download PDF

32. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

Author

Cesana, Clara, primary, Klersy, Catherine, additional, Brando, Bruno, additional, Nosari, Annamaria, additional, Scarpati, Barbara, additional, Scampini, Linda, additional, Molteni, Alfredo, additional, Nador, Guido, additional, Santoleri, Luca, additional, Formenti, Marta, additional, Valentini, Marina, additional, Mazzone, Antonino, additional, Morra, Enrica, additional, and Cairoli, Roberto, additional

Published
2008
Full Text
View/download PDF

41. Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

Author

Cesana, Clara, Klersy, Catherine, Brando, Bruno, Nosari, Annamaria, Scarpati, Barbara, Scampini, Linda, Molteni, Alfredo, Nador, Guido, Santoleri, Luca, Formenti, Marta, Valentini, Marina, Mazzone, Antonino, Morra, Enrica, and Cairoli, Roberto

Subjects
*MYELODYSPLASTIC syndromes, *DYSPLASIA, *BONE marrow diseases, *CELLS
Abstract

Abstract: We studied circulating (C)CD34+ cells by flow cytometry in 96 patients with myelodisplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34+ counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/μl were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/μl more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/μl cut-off of circulating CD34+ cells retains prognostic utility, especially in intermediate-risk MDS. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

42. Clinical Characteristics and Outcome of Immunoglobulin M–Related Disorders

Author

Cesana, Clara, Barbarano, Luciana, Miqueleiz, Sara, Lucchesini, Camilla, Ricci, Francesca, Varettoni, Marzia, Filippini, Davide, Lazzarino, Mario, and Morra, Enrica

Abstract

We analyzed the clinical features and prognostic factors for transformation of immunoglobulin M–related disorders (IgM-RDs) to malignant lymphoproliferative disease (MLD) in 83 patients with IgM-RDs. We studied 19 patients with type I cryoglobulinemias, 56 patients with type II cryoglobulinemias, 5 patients with peripheral neuropathies (PNs), and 3 patients with idiopathic thrombocytopenic purpuras. Fourteen patients with cryoglobulinemias presented with mild to moderate hepatomegaly with or without splenomegaly. Fourteen patients with type II cryoglobulinemias had arthralgias and/or vascular purpura (12 receiving corticosteroids), and 7 presented with PN. These latter patients and those with PNs without cryoglobulinemia were treated with steroids, cyclophosphamide, or polychemotherapy with/without plasma-exchange. Cumulative probability of evolution to MLD at 5 years was 15% (95% CI; 5%-25%). At a median of 62 months (12-195 months), 8 cases of IgM-RDs (8.4%) evolved to overt Waldenström's macroglobulinemia (n = 6), 1 case to non-Hodgkin's lymphoma, and 1 case to B-cell chronic lymphocytic leukemia. At univariate analysis, male sex (P= 0.02), IgM level = 3 g/dL (P< 0.0001), detectable Bence Jones proteinuria (P= 0.0005), lymphocytosis (P= 0.049), and high erythrocyte sedimentation rate (P= 0.003) significantly correlated with the evolution risk. Age, blood cell counts, ß2-microglobulin level, degree of marrow lymphoplasmacytic infiltration, type of cryoglobulinemia, and hepatitis C virus positivity did not correlate with transformation. Although IgM-RDs represent a distinct clinical entity frequently requiring treatment in view of the IgM-related symptoms, their evolution probability and prognostic factors for malignant transformation seem to widely overlap those described for asymptomatic IgM monoclonal gammopathies.

Published
2004
Full Text
View/download PDF

43. Prognostic Factors for Transformation in Asymptomatic Immunoglobulin M Monoclonal Gammopathies

Author

Morra, Enrica, Cesana, Clara, Klersy, Catherine, Barbarano, Luciana, Miqueleiz, Sara, Varettoni, Marzia, Lucchesini, Camilla, Ricci, Francesca, and Lazzarino, Mario

Abstract

We evaluated the risk of transformation of asymptomatic immunoglobulin (Ig) M monoclonal gammopathy (aIgM-MG) into symptomatic lymphoproliferative disease in 384 patients, in subgroups of patients with IgM MG of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (sWM). One hundred seventy-two patients with aIgM-MG with bone marrow (BM) histopathology and immunophenotyping were available for analysis. After a median of 45 months (range, 12-233 months), 45 cases of aIgM-MG (11.7%) evolved into lymphoproliferative disease, as follows: symptomatic WM (n = 41), non-Hodgkin's lymphoma (NHL; n = 2), IgM multiple myeloma (IgM-MM; n = 1), and primary amyloidosis (n = 1). Cumulative transformation probability at 5 and 10 years was 8% and 29%, respectively. The parameters significantly correlated with evolution were, at univariate analysis, BM lymphoplasmacytic infiltration, high erythrocyte sedimentation rate, hemoglobin (Hb) level, IgM size, and peripheral lymphocytosis; at multivariate analysis, the parameters were IgM size and peripheral lymphocytosis, with Hb level associated with a trend toward higher progression risk. Of the 138 cases of IgM-MGUS, 14 (10.1%) evolved (13 WM, 1 IgM-MM) after a median of 75 months (range, 12-117 months); of the 34 cases of sWM, 13 (38.2%) progressed to WM after 55 months (range, 13-154 months). In patients with IgM-MGUS, event-free survival at 5 and 10 years was 95% and 83%, respectively, and in patients with sWM, 77% and 42%, respectively (P= 0.0001). Among patients with aIgM-MG, those at high risk of evolution are patients with sWM, a distinct entity with clear BM evidence of NHL.

Published
2004
Full Text
View/download PDF

44. Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-α.

Author

Cesana, Clara, Brando, Bruno, Boiani, Elisa, Chiodo, Federico, Cairoli, Roberto, Intropido, Liliana, and Morra, Enrica

Subjects
*THERAPEUTIC use of interferons, *LEUKEMIC reticuloendotheliosis treatment, *AUTOIMMUNE hemolytic anemia, *AUTOIMMUNE disease treatment
Abstract

Discusses the use of interferon-alpha in treating hairy cell (HC) leukemia. Capacity of the treatment to enhance autoimmunity; Occurrence of HCL-related autoimmune hemolytic anemia (AIHA); Finding that immunosuppression is frequently unsuccessful in HCL-related AIHA.

Published
2002
Full Text
View/download PDF

45. Peripheral Blood CD34+Cell Patterns in Myelodysplastic Syndromes Stratified According to International Prognostic Scoring System (IPSS).

Author

Cesana, Clara, Rodeschini, Ornella, Molteni, Alfredo, Santoleri, Luca, Mella, Mario, Rovere, Elisabetta, Monguzzi, Antonio, and Morra, Enrica

Abstract

Introduction: The International Prognostic Scoring System (IPSS) better defines the outcome and transformation risk of myelodysplastic syndromes (MDS) than FAB classification. The latter was previously found to identify different patterns of peripheral blood (PB) CD34+cells in MDS. Whether a correlation exists between PB CD34+cells and IPSS classification of MDS is undetermined.

Published
2005
Full Text
View/download PDF

46. Regeneration-associated WNT Signaling Is Activated in Long-term Reconstituting AC133bright Acute Myeloid Leukemia Cells.

Author

Beghini, Alessandro, Corlazzoli, Francesca, Del Giacco, Luca, Re, Matteo, Lazzaroni, Francesca, Brioschi, Matteo, Valentini, Giorgio, Ferrazzi, Fulvia, Ghilardi, Anna, Righi, Marco, Turrini, Mauro, Mignardi, Marco, Cesana, Clara, Bronte, Vincenzo, Nilsson, Mats, Morra, Enrica, and Cairoli, Roberto

Subjects
*ACUTE myeloid leukemia, *STEM cell research, *HEMATOPOIETIC stem cells, *CATENINS, *LEUKEMIA
Abstract

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by two molecularly distinct self-renewing leukemic stem cell (LSC) populations most closely related to normal progenitors and organized as a hierarchy. A requirement for WNT/ß-catenin signaling in the pathogenesis of AML has recently been suggested by a mouse model. However, its relationship to a specific molecular function promoting retention of self-renewing leukemia-initiating cells (LICs) in human remains elusive. To identify transcriptional programs involved in the maintenance of a self-renewing state in LICs, we performed the expression profiling in normal (n = 10) and leukemic (n = 33) human long-term reconstituting AC133+ cells, which represent an expanded cell population in most AML patients. This study reveals the ligand-dependent WNT pathway activation inAC133bright AML cells and shows a diffuse expression and release ofWNT10B, a hematopoietic stem cell regenerative-associated molecule. The establishment of a primary AC133+ AML cell culture (A46) demonstrated that leukemia cells synthesize and secrete WNT ligands, increasing the levels of dephosphorylated ß-catenin in vivo. We tested the LSC functional activity in AC133+ cells and found significant levels of engraftment upon transplantation of A46 cells into irradiated Rag2-/-γc-/- mice. Owing to the link between hematopoietic regeneration and developmental signaling, we transplanted A46 cells into developing zebrafish. This system revealed the formation of ectopic structures by activating dorsal organizer markers that act bright downstream of the WNT pathway. In conclusion, our findings suggest that AC133 LSCs are promoted by misappropriating homeostatic WNT programs that control hematopoietic regeneration. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

47. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.

Author

Cesana C, Nosari AM, Klersy C, Miqueleiz S, Rossi V, Ferrando P, Valentini M, Barbarano L, and Morra E

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bacterial Infections mortality, Bacterial Infections pathology, Dexamethasone administration & dosage, Doxorubicin administration & dosage, Escherichia coli isolation & purification, Escherichia coli Infections epidemiology, Escherichia coli Infections mortality, Escherichia coli Infections pathology, Female, Humans, Klebsiella Infections epidemiology, Klebsiella Infections mortality, Klebsiella Infections pathology, Klebsiella pneumoniae isolation & purification, Male, Middle Aged, Multiple Myeloma epidemiology, Multiple Myeloma mortality, Pseudomonas Infections epidemiology, Pseudomonas Infections mortality, Pseudomonas Infections pathology, Pseudomonas aeruginosa isolation & purification, Retrospective Studies, Risk Factors, Severity of Illness Index, Staphylococcal Infections epidemiology, Staphylococcal Infections mortality, Staphylococcal Infections pathology, Staphylococcus aureus isolation & purification, Staphylococcus epidermidis isolation & purification, Vincristine administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bacterial Infections epidemiology, Multiple Myeloma drug therapy, Multiple Myeloma microbiology
Abstract

Background and Objectives: We evaluated bacterial infections (BIs) in patients with multiple myeloma (MM) treated with two different schedules of vincristine-adriamycin-dexamethasone (VAD)., Design and Methods: Ninety-seven patients were studied during 340 VAD cycles. VAD was given by either continuous intravenous infusion (CII) to hospitalized patients or rapid intravenous infusion (RII) to outpatients. The characteristics of patients and VAD schedules were retrospectively analyzed to detect correlations with the incidence of BI., Results: By analyzing each VAD cycle, we found that profound hypogammaglobulinemia (p=0.06) and post-treatment neutropenia (p=0.08) were associated with a trend for a higher risk of infection, while renal function impairment was significantly correlated with BI risk at both univariate (p<0.02) and multivariate (p<0.002) analyses. Evaluating only the first 4 months of therapy, characterized by a significantly higher incidence of BI than the later period (p<0.0001), previously untreated disease was significantly correlated with BI risk (p<0.04), while male sex (p=0.06), CII schedule (p=0.07), and profound hypogammaglobulinemia (p=0.1) were associated with a tendency to a higher risk of infection; however, at multivariate analysis the latter two parameters independently predicted BI probability (p<0.015 and p<0.03, respectively) as did previously untreated disease (p<0.025). The high probability of CII-related infection was demonstrated to depend on the frequent development of nosocomial infections., Interpretation and Conclusions: Patients with profound hypogammaglobulinemia who receive VAD as first line treatment are at a major risk of BI up to the completion of the fourth month of therapy. In this setting hospitalization should be avoided and, if patients require admission, antibacterial prophylaxis with intravenous immunoglobulins could be appropriate and effective.

Published
2003

48. Successful treatment with voriconazole of cerebral aspergillosis in an hematologic patient.

Author

Marbello L, Nosari A, Carrafiello G, Anghilieri M, Cesana C, Cafro AM, D'Avanzo G, and Morra E

Subjects
Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Middle Aged, Opportunistic Infections drug therapy, Pyrimidines therapeutic use, Treatment Outcome, Triazoles therapeutic use, Voriconazole, Antifungal Agents therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell complications, Neuroaspergillosis drug therapy
Published
2003

Catalog

Books, media, physical & digital resources
See catalog results